Coherus BioSciences, Inc. (CHRS)

Coherus BioSciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	259.78	102.89	63.55	417.2	541.16	177.67
Short-Term Investments	0	14.86	128.13	0	0	0
Cash & Cash Equivalents	259.78	117.75	191.68	417.2	541.16	177.67
Cash Growth	102.81%	-38.57%	-54.05%	-22.91%	204.59%	145.38%
Receivables	284.15	260.52	109.96	123.02	157.05	141.99
Inventory	127.62	130.1	115.05	93.25	92.19	55.07
Other Current Assets	-44.07	-32.74	-35.46	-31.15	-22.91	-31.72
Total Current Assets	627.48	475.63	381.23	602.32	767.48	343.01
Property, Plant & Equipment	4.19	5.12	8.75	7.81	10.11	16.49
Long-Term Investments	0	0	0	0	0	0.24
Goodwill and Intangibles	57.1	71.67	5.93	3.56	3.56	3.56
Other Long-Term Assets	74.78	77.18	84.93	65.64	60.5	45.63
Total Long-Term Assets	136.07	153.97	99.61	77.01	74.17	65.92
Total Assets	763.55	629.6	480.85	679.33	841.65	408.93
Accounts Payable	69.06	35.22	11.53	16.16	15.2	25.99
Current Debt	175	0	0	0	0	0
Other Current Liabilities	294.24	296.55	127.17	149.17	130.45	88.98
Total Current Liabilities	538.3	331.77	138.69	165.33	145.65	114.97
Long-Term Debt	304.35	478.7	476.1	415.53	413.97	188.64
Other Long-Term Liabilities	2.73	12.56	3.47	0.75	1.05	0.1
Total Long-Term Liabilities	307.09	491.26	479.57	416.28	415.02	188.74
Total Liabilities	845.39	823.03	618.27	581.61	560.68	303.71
Total Debt	479.35	478.7	476.1	415.53	413.97	188.64
Debt Growth	0.83%	0.54%	14.58%	0.38%	119.45%	82.98%
Retained Earnings	-1,476.63	-1,579.5	-1,341.61	-1,049.85	-762.75	-895
Comprehensive Income	-0.27	-0.25	-0.25	-0.27	-0.27	-0.56
Shareholders' Equity	-81.84	-193.43	-137.42	97.73	280.97	105.21
Net Cash / Debt	-219.58	-360.95	-284.42	1.66	127.19	-10.97
Net Cash / Debt Growth	-	-	-	-98.69%	-	-
Net Cash Per Share	-1.75	-3.83	-3.66	0.02	1.78	-0.15
Working Capital	89.17	143.86	242.54	437	621.83	228.04
Book Value Per Share	-0.73	-2.05	-1.77	1.29	3.94	1.51

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).